|
|
Blood, 15 January 2005, Vol. 105, No. 2, pp. 874-878.
Prepublished online as a Blood First Edition Paper on September 23, 2004; DOI 10.1182/blood-2004-04-1532.
Previous Article | Table of Contents | Next Article 
TRANSPLANTATION
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas
Amrita Krishnan,
Arturo Molina,
John Zaia,
David Smith,
Debbie Vasquez,
Neil Kogut,
Peter M. Falk,
Joseph Rosenthal,
Joseph Alvarnas, and
Stephen J. Forman
From the City of Hope Hematologic Neoplasia Program, City of Hope Cancer Center, Division of Hematology and Hematopoietic Stem Cell Transplantation, Duarte, CA.
The treatment of HIV-associated lymphoma has changed since the widespread use of highly active antiretroviral therapy. HIV-infected individuals can tolerate more intensive chemotherapy, as they have better hematologic reserves and fewer infections. This has led to higher response rates in patients with HIV-associated Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) treated with chemotherapy in conjunction with antiretroviral therapy. However, for patients with refractory or relapsed disease, salvage chemotherapy still offers little chance of long-term survival. In the non-HIV setting, patients with relapsed Hodgkin disease (HD) or non-Hodgkin lymphoma (NHL) have a better chance of long-term remission with high-dose chemotherapy with autologous stem cell rescue (ASCT) compared with conventional salvage chemotherapy. In a prior report we demonstrated that this approach is well tolerated in patients with underlying immunodeficiency from HIV infection. Furthermore, similar engraftment to the non-HIV setting and low infectious risks have been observed. Herein, we expand upon this early experience with the largest single institution series of 20 patients. With long-term follow-up we demonstrate that ASCT can lead to an 85% progression-free survival, which suggests that this approach may be potentially curative in select patients with relapsed HIV-associated HD or NHL.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Autologous stem cell transplantation for HIV-infected individuals with relapsed lymphomas: no longer an experimental strategy
- Cecilia Simonelli and Mariagrazia Michieli
Blood 2005 105: 439-440.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
G. C. Persad, R. F. Little, and C. Grady
Including Persons With HIV Infection in Cancer Clinical Trials
J. Clin. Oncol.,
March 1, 2008;
26(7):
1027 - 1032.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Wolf, V. Rickerts, S. Staszewski, S. Kriener, B. Wassmann, G. Bug, M. Bickel, P. Gute, H.R. Brodt, and H. Martin
First case of successful allogeneic stem cell transplantation in an HIV-patient who acquired severe Aplastic Anemia
Haematologica,
April 1, 2007;
92(4):
e56 - e58.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hentrich, L. Maretta, K. U. Chow, J. R. Bogner, D. Schurmann, P. Neuhoff, H. Jager, D. Reichelt, M. Vogel, M. Ruhnke, et al.
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study
Ann. Onc.,
June 1, 2006;
17(6):
914 - 919.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Masur
Management of Patients with HIV in the Intensive Care Unit.
Proceedings of the ATS,
January 1, 2006;
3(1):
96 - 102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. H. Navarro and L. D. Kaplan
AIDS-related lymphoproliferative disease
Blood,
January 1, 2006;
107(1):
13 - 20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. T. Lim and A. M. Levine
Recent Advances in Acquired Immunodeficiency Syndrome (AIDS)-related Lymphoma
CA Cancer J Clin,
July 1, 2005;
55(4):
229 - 241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. T. Lim, R. Karim, B. N. Nathwani, A. Tulpule, B. Espina, and A. M. Levine
AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre-Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard Chemotherapy
J. Clin. Oncol.,
July 1, 2005;
23(19):
4430 - 4438.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|